Clinical Trial Update: BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating BGJ398 in combination with imatinib in untreated advanced GIST has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• BGJ398 (BGJ398)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Gastrointestinal Stromal Tumor (GIST) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-30